Merck Says Completes Enrolment Of Evobrutinib Phase III Clinical Trials

T-Reuters2021-10-04

Merck KGaA: Merck Completes Enrolment Of Evobrutinib Phase Iii Clinical Trials Ahead Of Ectrims 2021.Investigational Evobrutinib Is The First Bruton’S Tyrosine Kinase (Btk) Inhibitor To Complete Phase Iii Clinical Trial Enrolment In Relapsing Multiple Sclerosis (Rms).Data From Oral Presentations At Ectrims Show Evobrutinib Has A Positive Impact On Important Biomarkers Of Disease Progression.New Independent Data Also Presented Found That Patients Treated With Mavenclad® (Cladribine Tablets) Had Increased Antibody Igg Titer Levels Similar To That Of The General Population After A Complete Course Of An Mrna Covid-19 Vaccine.Further Company Coverage:. (Berlin Speed Desk).

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

发表看法
9